<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924818</url>
  </required_header>
  <id_info>
    <org_study_id>PO16020</org_study_id>
    <nct_id>NCT02924818</nct_id>
  </id_info>
  <brief_title>Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases</brief_title>
  <acronym>RINNOPARI</acronym>
  <official_title>Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases: The RINNOPARI Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <brief_summary>
    <textblock>
      Chronic inflammatory pulmonary diseases including chronic obstructive pulmonary disease
      (COPD), interstitial lung diseases (ILD), bronchiectasis, and cystic fibrosis (CF) are
      characterized by lung inflammation and remodelling. Clinical, functional, microbiological,
      biological, pathological and prognosis features are highly variable and heterogeneous. A
      precise phenotyping is a key-element to better understanding the pathophysiology of these
      chronic inflammatory diseases and to develop innovative treatment strategies.

      The objectives of this prospective study is to analyze the clinical, demographic, biological,
      morphological, pathological, and microbiological characteristics in a cohort of patients
      diagnosed with COPD, ILD, bronchiectasis, and CF. The associations between clinical,
      demographic, biological, morphological, pathological, and microbiological features will be
      assessed.

      The Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases (the
      RINNOPARI Project: Recherche et Innovation en Pathologie Respiratoire Inflammatoire) is a
      monocentric study conducted at the University Hospital of Reims, France. Adult patients (&gt;18
      year-old) followed at the University Hospital of Reims and diagnosed with COPD, ILD,
      bronchiectasis, or CF will be considered for inclusion. Patients will sign an informed
      consent for inclusion. Exclusion criteria include &quot;subjects protected by the law&quot; as required
      by the French authorities. Control patients with no respiratory diseases after clinical and
      pulmonary function tests assessment will be also included. The expected number of patients
      included is 225 (COPD, n=100; CF, n=25; bronchiectasis, n=25; ILD, n=25; controls, n=50).
      Inclusion will be conducted for 36 months from September 2016 (9/30/2016) to September 2019
      (9/30/2019).

      For all COPD, ILD, bronchiectasis, and CF patients included, data will be registered at
      inclusion, and at follow-up visits for 10 years. Patients will be followed-up as usual care
      with no specific therapeutic intervention. For control patients, data will be registered at
      inclusion with no follow-up.

      Data will be registered in a centralized anonymized database. The characteristics of the
      patients will be described as mean and standard deviation for quantitative data and as number
      and percentages for qualitative data. Comparisons and associations between groups and
      variables will be analyzed by Student, Wilcoxon, Chi2, Fischer exact, and Spearman tests as
      applicable. A p&lt;0.05 will be considered as significant.

      This study should help to better characterize clinical, demographic, biological,
      morphological, pathological, and microbiological characteristics and phenotypes in chronic
      inflammatory respiratory diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">November 2029</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific measurements: cytokines (Th1, Th2, Th17, Tc1, Tc2, Tc17) measurements in blood sample</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific measurements: cytokines (Th1, Th2, Th17, Tc1, Tc2, Tc17) measurements in blood sample</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Chronic Inflammatory Pulmonary Diseases</condition>
  <arm_group>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pulmonary function test</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>microbiology</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>histology</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>imaging</intervention_name>
    <arm_group_label>Chronic Obstructive Pulmonary disease (COPD)</arm_group_label>
    <arm_group_label>Cystic Fibrosis (CF)</arm_group_label>
    <arm_group_label>bronchiectasis</arm_group_label>
    <arm_group_label>Interstitial lung disease (ILD)</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 year-old) with COPD, CF, bronchiectasis or ILD

        Exclusion Criteria:

          -  &lt;18 year-old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaëtan Deslée</last_name>
    <phone>326787611</phone>
    <phone_ext>33</phone_ext>
    <email>gdeslee@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>France</city>
        <state>Reims</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

